DA/VVC/SMD/VGU/26/017 June 2026

Food and Drugs Authority
Safety Monitoring Department/ National Pharmacovigilance Center

Adverse Reaction Reporting Scoreboard

Outlook of Regional Performance

Overview of Regional Performance

The Safety Monitoring Department/ National Pharmacovigilance Center of the Food and Drugs Authority publishes the Adverse Reaction Reporting Scoreboard every two months to offer quantitative information on the training initiatives and individual case safety reports (ICSRs) that are received from the sixteen regions. To promote better diagnosis, management and reporting safety issues, the scoreboard is intended to compare reporting trends of adverse reactions to medications, vaccinations and other health- related issues at the regional levels. It is anticipated that this will contribute to increasing the number of adverse events that are reported which will assist identify new safety signals for marketed medications, vaccines, and other health goods.

Pharmacovigilance Training Programs

The FDA had 103 pharmacovigilance (PV) training programs between May to June 2026 in the 16 regions with a total of 2,400 participants. Figure 1 shows the performance of the regions in terms of the number of PV training programs. The Upper East region leads the chart with 25 PV training programs followed by the Bono region with 18 PV training programs.




Fig. 1: The number of PV training programs organized in the regions May – June 2026.

Figure 2 shows the percentage of the professional backgrounds of the participants trained during the PV training programs. Most of the participants (24.7%) were students professionals.




Fig. 2: Professional background of participants for the PV training programs in percentage.

Adverse Reactions Reported

Three hundred and ninety (390) ICSRs were received for medicines, vaccines, and other health products during the period under review. The Eastern region recorded the highest absolute number of reports followed by the Greater Accra region. The Eastern region recorded the highest reporting rate of 37 reports per 1,000,000 population followed by the Bono East region with a reporting rate of 21 reports per 1,000,000 (Figure 4) based on the 2021 population and housing census.




Fig. 3. Number of adverse reaction reports received in the region.




Fig. 4: Regional reporting rate per 1,000,000 population (2021 Population and Housing Census)

You may reach out to the Safety Monitoring Department on the underlisted contacts for information on the safety of medicines, vaccines, blood and blood products, medical devices and other regulated health products:

Telephone : 024 4310 297

Email : drug.safety@fda.gov.gh